Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Weyerhaeuser heads into its October 29 earnings print with short sellers adding exposure at a notable clip, options traders increasingly bullish, and a live index rebalance decision hovering over the stock.
The most mechanically interesting pressure point this week is the MSCI review. ORTEX puts the probability of WY being deleted from the MSCI USA, MSCI World, MSCI North America and MSCI Kokusai indices at 30% each, with the rank date falling on October 19. The stock needs to close above $20.80 to stay above the exit line. At $18.97, it is 9.6% below that threshold. If deletion is confirmed at the November 11 announcement, trackers would need to sell an estimated $816M worth of shares by November 30, equivalent to 6.7 days of normal volume. The same review could simultaneously add WY to the MSCI USA Small and MSCI World Small indices, generating $544M and $272M of buying flow respectively. The two forces would partially offset, but the sequencing and net flow matter. This is a price-sensitive binary that resolves in five days.
Short interest has climbed 13% over the past week to 4.1% of the free float, reaching approximately 29.2 million shares. That is the sharpest weekly build in several months and follows a period of relative stability through September. Borrowing costs remain negligible at 0.37%, and availability is extremely loose at 2,267%, meaning there is no friction preventing further short additions. The borrow market is not signalling a squeeze, it is signalling an easy trade for anyone wanting to lean against the name ahead of the MSCI decision. The ORTEX short score has edged up to 39.8, still in the lower half of its range, suggesting the build is not yet extreme by historical standards.
Options positioning cuts the other way. The put/call ratio has dropped to 0.36, nearly two standard deviations below its 20-day average of 0.45. That is close to the 52-week low of 0.30 and represents the most call-heavy positioning of the past year. Options traders are effectively buying the B of A upgrade thesis, that the stock is oversold at a steep NAV discount and that cyclical headwinds from wood products transportation constraints are temporary. The EPS surprise factor score ranks in the 97th percentile, meaning the company has an unusually strong track record of beating estimates. The last earnings print, on July 30, produced a 2.4% next-day gain and a 4.1% five-day gain. The prior comparable event produced a 7.4% next-day move. Both readings were positive.
The Street remains broadly constructive despite a wave of target cuts. Eight analysts carry Buy-equivalent ratings against two Holds, with a consensus mean target of $27.82. The gap to the current price implies roughly 47% upside, though the path of recent revisions is one-way downward. Citigroup trimmed to $21 from $29 in early October. Truist cut to $24 from $28 on October 12. JP Morgan lowered to $28 from $31 in September. The valuation picture is also stretched in the wrong direction for bears. The EV/EBITDA multiple has risen 0.5 turns over the past 30 days as the stock fell, now running at 14.3x. The price-to-book has dropped to 1.5x on the same period, having come off sharply. On ORTEX factor scores, 90-day EPS momentum ranks in the 93rd percentile, yet the 30-day momentum score sits at just the 9th percentile, capturing how quickly near-term estimates have deteriorated relative to the longer-run trend.
The key date is October 19, when MSCI takes its market-cap snapshot for the November review. Whether WY closes above or below $20.80 that day will determine whether the index flow is a headwind or, in combination with the small-cap additions, broadly neutral. Earnings on October 29 follow fifteen days later. The two events in quick succession make this one of the more data-dense fortnights the stock has faced this year.
See the live data behind this article on ORTEX.
Open WY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
